Cargando…
Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model
Liuweiwuling Tablet (LWWL) is a licensed Chinese patent medicine (approval number: Z20060238) included in the national health insurance for anti-inflammation of chronic HBV infection, whereas its anti-HBV effect remains clarification. The study aimed to clarify its antiviral effect and related mecha...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578813/ https://www.ncbi.nlm.nih.gov/pubmed/34776974 http://dx.doi.org/10.3389/fphar.2021.756975 |
_version_ | 1784596313667534848 |
---|---|
author | Ge, Fei-lin Si, Lan-lan Yang, Yan Li, Yuan-hua Lv, Zhong-lin Liu, Wen-hui Liao, Hao Wang, Jun Zou, Jun Li, Le Li, Hui Zhang, Zi-lin Wang, Jia-bo Lu, Xue-chun Xu, Dong-ping Bai, Zhao-fang Liu, Yan Xiao, Xiao-he |
author_facet | Ge, Fei-lin Si, Lan-lan Yang, Yan Li, Yuan-hua Lv, Zhong-lin Liu, Wen-hui Liao, Hao Wang, Jun Zou, Jun Li, Le Li, Hui Zhang, Zi-lin Wang, Jia-bo Lu, Xue-chun Xu, Dong-ping Bai, Zhao-fang Liu, Yan Xiao, Xiao-he |
author_sort | Ge, Fei-lin |
collection | PubMed |
description | Liuweiwuling Tablet (LWWL) is a licensed Chinese patent medicine (approval number: Z20060238) included in the national health insurance for anti-inflammation of chronic HBV infection, whereas its anti-HBV effect remains clarification. The study aimed to clarify its antiviral effect and related mechanisms. HepG2.2.15 cells (wild-type HBV-replicating cells) and HepG2. A64 cells (entecavir-resistant HBV-replicating cells) were used for in vitro test. Hydrodynamic injection-mediated HBV-replicating mouse model was used for in vivo test. Active compounds and related mechanisms for antiviral effect of LWWL were analyzed using network pharmacology and transcriptomics. The inhibition rates of LWWL (0.8 mg/ml) on HBV DNA, HBsAg, and pgRNA were 57.06, 38.55, and 62.49% in HepG2.2.15 cells, and 51.57, 17.57, and 53.88% in HepG2. A64 cells, respectively. LWWL (2 g kg(−1) d(−1) for 4 weeks)-treated mice had 1.16 log(10) IU/mL decrease of serum HBV DNA, and more than 50% decrease of serum HBsAg/HBeAg and hepatic HBsAg/HBcAg. Compared to tenofovir control, LWWL was less effective in suppressing HBV DNA but more effective in suppressing HBV antigens. Thirteen differentially-expressed genes were found in relation to HBV-host interaction and some of them were enriched in interferon (IFN)-β pathway in LWWL-treated HepG2.2.15 cells. CD3(+)CD4(+) T-cell frequency and serum IFN-γ were significantly increased in LWWL-treated mice compared to LWWL-untreated mice. Among 26 compounds with potential anti-HBV effects that were predicted by network pharmacology, four compounds (quercetin, luteolin, wogonin, and kaempferol) were experimentally confirmed to have antiviral potency. In conclusion, LWWL had potent inhibitory effect on both wild-type and entecavir-resistant HBV, which might be associated with increasing IFN-β and IFN-γ production. |
format | Online Article Text |
id | pubmed-8578813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85788132021-11-11 Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model Ge, Fei-lin Si, Lan-lan Yang, Yan Li, Yuan-hua Lv, Zhong-lin Liu, Wen-hui Liao, Hao Wang, Jun Zou, Jun Li, Le Li, Hui Zhang, Zi-lin Wang, Jia-bo Lu, Xue-chun Xu, Dong-ping Bai, Zhao-fang Liu, Yan Xiao, Xiao-he Front Pharmacol Pharmacology Liuweiwuling Tablet (LWWL) is a licensed Chinese patent medicine (approval number: Z20060238) included in the national health insurance for anti-inflammation of chronic HBV infection, whereas its anti-HBV effect remains clarification. The study aimed to clarify its antiviral effect and related mechanisms. HepG2.2.15 cells (wild-type HBV-replicating cells) and HepG2. A64 cells (entecavir-resistant HBV-replicating cells) were used for in vitro test. Hydrodynamic injection-mediated HBV-replicating mouse model was used for in vivo test. Active compounds and related mechanisms for antiviral effect of LWWL were analyzed using network pharmacology and transcriptomics. The inhibition rates of LWWL (0.8 mg/ml) on HBV DNA, HBsAg, and pgRNA were 57.06, 38.55, and 62.49% in HepG2.2.15 cells, and 51.57, 17.57, and 53.88% in HepG2. A64 cells, respectively. LWWL (2 g kg(−1) d(−1) for 4 weeks)-treated mice had 1.16 log(10) IU/mL decrease of serum HBV DNA, and more than 50% decrease of serum HBsAg/HBeAg and hepatic HBsAg/HBcAg. Compared to tenofovir control, LWWL was less effective in suppressing HBV DNA but more effective in suppressing HBV antigens. Thirteen differentially-expressed genes were found in relation to HBV-host interaction and some of them were enriched in interferon (IFN)-β pathway in LWWL-treated HepG2.2.15 cells. CD3(+)CD4(+) T-cell frequency and serum IFN-γ were significantly increased in LWWL-treated mice compared to LWWL-untreated mice. Among 26 compounds with potential anti-HBV effects that were predicted by network pharmacology, four compounds (quercetin, luteolin, wogonin, and kaempferol) were experimentally confirmed to have antiviral potency. In conclusion, LWWL had potent inhibitory effect on both wild-type and entecavir-resistant HBV, which might be associated with increasing IFN-β and IFN-γ production. Frontiers Media S.A. 2021-10-27 /pmc/articles/PMC8578813/ /pubmed/34776974 http://dx.doi.org/10.3389/fphar.2021.756975 Text en Copyright © 2021 Ge, Si, Yang, Li, Lv, Liu, Liao, Wang, Zou, Li, Li, Zhang, Wang, Lu, Xu, Bai, Liu and Xiao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ge, Fei-lin Si, Lan-lan Yang, Yan Li, Yuan-hua Lv, Zhong-lin Liu, Wen-hui Liao, Hao Wang, Jun Zou, Jun Li, Le Li, Hui Zhang, Zi-lin Wang, Jia-bo Lu, Xue-chun Xu, Dong-ping Bai, Zhao-fang Liu, Yan Xiao, Xiao-he Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model |
title | Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model |
title_full | Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model |
title_fullStr | Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model |
title_full_unstemmed | Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model |
title_short | Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model |
title_sort | chinese patent medicine liuweiwuling tablet had potent inhibitory effects on both wild-type and entecavir-resistant hepatitis b virus (hbv) in vitro and effectively suppressed hbv replication in mouse model |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578813/ https://www.ncbi.nlm.nih.gov/pubmed/34776974 http://dx.doi.org/10.3389/fphar.2021.756975 |
work_keys_str_mv | AT gefeilin chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT silanlan chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT yangyan chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT liyuanhua chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT lvzhonglin chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT liuwenhui chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT liaohao chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT wangjun chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT zoujun chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT lile chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT lihui chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT zhangzilin chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT wangjiabo chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT luxuechun chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT xudongping chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT baizhaofang chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT liuyan chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel AT xiaoxiaohe chinesepatentmedicineliuweiwulingtablethadpotentinhibitoryeffectsonbothwildtypeandentecavirresistanthepatitisbvirushbvinvitroandeffectivelysuppressedhbvreplicationinmousemodel |